Pharmaceutical compositions for the prevention or treatment of cartilage, bone, and joint diseases, and screening methods for drugs for the prevention or treatment of cartilage, bone, and joint diseases.

Inhibiting semaphorin 4D-plexin B2 signaling with specific inhibitors addresses the issue of articular cartilage destruction in chronic diseases by reducing matrix metalloproteinase expression, offering therapeutic benefits for conditions like rheumatoid arthritis and osteoarthritis.

JP7884836B2Active Publication Date: 2026-07-06OSAKA UNIVERSITY
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2022571994
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-12-23
Filing Date
2021-11-25
Publication Date
2026-07-06
Estimated Expiration
2041-11-25

AI Technical Summary

Technical Problem

Current technologies do not effectively target inflammatory cytokines responsible for articular cartilage destruction in chronic cartilage, bone, and joint diseases such as rheumatoid arthritis and osteoarthritis, with limited understanding of immune cell interactions with chondrocytes in disease development.

Method used

Pharmaceutical compositions that inhibit semaphorin 4D-plexin B2 signaling, including inhibitors of plexin B2, c-Met, Traf2, IκBζ, and CEBPδ, are developed to target and reduce the expression or function of these inflammatory cytokines, along with a screening method to identify such inhibitors.

Benefits of technology

The compositions and method effectively inhibit cartilage destruction by reducing matrix metalloproteinase expression, thereby providing therapeutic benefits for diseases like rheumatoid arthritis and osteoarthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007884836000005
    Figure 0007884836000005
  • Figure 0007884836000006
    Figure 0007884836000006
  • Figure 0007884836000007
    Figure 0007884836000007
Patent Text Reader

Abstract

The present invention provides a pharmaceutical composition for preventing or treating cartilage / bone / joint diseases, the pharmaceutical composition containing, as active ingredients, a substance that inhibits the signal transduction of semaphorin 4D-plexin B2, for example: a substance that inhibits the binding of plexin-B2 and semaphoring 4D; a substance that inhibits the binding of c-Met and semaphorin 4D; a substance that inhibits the binding of plexin B2 and Traf2; and a substance that inhibits the binding of plexin B2 and c-Met. In addition, the present invention provides a method for screening a drug for preventing or treating cartilage / bone / joint diseases, the method comprising a step for selecting a substance to be tested that inhibits the signal transduction of semaphorin 4D-plexin B2.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Micromolecular c-Met protein kinase inhibitor

    CN103030654A

  • 7-azaindole derivatives as c-Met kinase inhibitors

    JP2010507618A

  • Osteogenesis promoter

    WO2012157237A1

  • NOX inhibitor and NFΚb inhibitor containing methoxyflavone

    WO2015170683A1

  • Dual inhibition of plexin-b1 and plexin-b2

    WO2020165094A1